AZD 8566Alternative Names: AZD8566
Latest Information Update: 12 Aug 2010
At a glance
- Originator AstraZeneca
- Class Antirheumatics
- Mechanism of Action CCR5 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 29 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 31 Aug 2008 Phase-I clinical trials in Rheumatoid arthritis in United Kingdom (PO)